Search

Your search keyword '"Marie Ouache"' showing total 4 results
Start Over Author "Marie Ouache" Topic medicine.disease
4 results on '"Marie Ouache"'

1. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction

Author

Y. Perel, Christopher P. Thomas, Jean Donadieu, J. Landman Parker, V. Minard Colin, Christiane Vermylen, Pascal Chastagner, Yves Bertrand, Marie Ouache, Frédéric Bernard, and Martine Munzer

Subjects
Male, Cancer Research, medicine.medical_specialty, medicine.drug_class, Pilot Projects, Gastroenterology, Antimetabolite, Langerhans cell histiocytosis, Refractory, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Chlorodeoxyadenosine, Humans, Infusions, Intravenous, Cladribine, business.industry, Cytarabine, Infant, Combination chemotherapy, medicine.disease, Hematologic Diseases, Survival Analysis, Surgery, Transplantation, Histiocytosis, Langerhans-Cell, Oncology, Chronic Disease, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

The aim of this study was to assess the efficacy and adverse effects of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (Ara-C) in children with refractory Langerhans cell histiocytosis (LCH) and haematopoietic dysfunction. Ten patients, with a median age at diagnosis of 0.5 years, were enrolled in this study. Treatment comprised at least two courses of Ara-C (1000mg/m 2 /d) and 2-CdA (9mg/m 2 /d) administered for 5d every 4 weeks; subsequent median follow-up was 2.8 years (range 0.03–6.4 years). Among the 7 patients who received at least two courses of therapy, disease activity decreased in 6 patients, and control of disease was achieved in all patients after a median delay of 5.5 months. All patients suffered World Health Organisation (WHO) grade 4 haematological toxicity. Two septic deaths occurred shortly after administration of the first course of 2-CdA/Ara-C; a third patient was withdrawn from the trial after the first course and subsequently died following haematopoietic stem cell transplantation. This series is small, but we conclude that 2-CdA and Ara-C combined chemotherapy probably has major activity in childhood refractory Langerhans cell histiocytosis.

Published
2005
Full Text
View/download PDF

2. Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009

Author

Jean-Claude Léonard, Pierre Mary, Michèle Bigorre, Jacques de Blic, Ralph Epaud, Makram Ziade, Marion Gillibert-Yvert, Isabelle Pin, Martine Le Merrer, Sébastien Héritier, Benoit de Courtivron, Marie Ouache, Véronique Houdoin, Brigitte Fauroux, Jeanne Wagnon, Pascal Chastagner, Francis Jaubert, Daniel Wendling, Christian Carrie, Liliane Boccon-Gibod, Jean Donadieu, J. Languepin, Véronique Forin, Yann Revillon, Yves Bertrand, Cécile Bost-Bru, Hubert Ducou Lepointe, Service de Génétique Médicale [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service d'AnatomoPathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], Conception et Test de Systèmes MICroélectroniques (SysMIC), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Necker - Enfants Malades [AP-HP], Département de Pédiatrie - CHRU de Grenoble, CHU Grenoble, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Physiologie, biologie des organismes, populations, interactions, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pneumologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Centre de référence des Histiocytoses, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire [Grenoble] (CHU), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (UMRS893), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP], Conception et Test de Systèmes MICroélectroniques ( SysMIC ), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier ( LIRMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de pneumologie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Service d'hématologie-immunologie-oncologie pédiatrique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
Male, medicine.medical_specialty, Pediatrics, Pleural effusion, Vascular Malformations, medicine.medical_treatment, Alpha interferon, lcsh:Medicine, Kaplan-Meier Estimate, 030218 nuclear medicine & medical imaging, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 03 medical and health sciences, 0302 clinical medicine, Epidemiology, medicine, Humans, Genetics(clinical), Pharmacology (medical), Child, Genetics (clinical), Retrospective Studies, Medicine(all), Respiratory distress, Diphosphonates, business.industry, Mortality rate, Research, lcsh:R, Interferon-alpha, General Medicine, Bone fracture, medicine.disease, 3. Good health, Radiation therapy, Thalidomide, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 030220 oncology & carcinogenesis, Female, France, Bone Diseases, business, medicine.drug
Abstract

Objective To document the epidemiological, clinical, histological and radiological characteristics of aggressive vascular abnormalities of bone in children. Study design Correspondents of the French Society of Childhood Malignancies were asked to notify all cases of aggressive vascular abnormalities of bone diagnosed between January 1988 and September 2009. Results 21 cases were identified; 62% of the patients were boys. No familial cases were observed, and the disease appeared to be sporadic. Mean age at diagnosis was 8.0 years [0.8-16.9 years]. Median follow-up was 3 years [0.3-17 years]. The main presenting signs were bone fracture (n = 4) and respiratory distress (n = 7), but more indolent onset was observed in 8 cases. Lung involvement, with lymphangiectasies and pleural effusion, was the most frequent form of extraosseous involvement (10/21). Bisphosphonates, alpha interferon and radiotherapy were used as potentially curative treatments. High-dose radiotherapy appeared to be effective on pleural effusion but caused major late sequelae, whereas antiangiogenic drugs like alpha interferon and zoledrenate have had a limited impact on the course of pulmonary complications. The impact of bisphosphonates and alpha interferon on bone lesions was also difficult to assess, owing to insufficient follow-up in most cases, but it was occasionally positive. Six deaths were observed and the overall 10-year mortality rate was about 30%. The prognosis depended mainly on pulmonary and spinal complications. Conclusion Aggressive vascular abnormalities of bone are extremely rare in childhood but are lifethreatening. The impact of anti-angiogenic drugs on pulmonary complications seems to be limited, but they may improve bone lesions.

Published
2010
Full Text
View/download PDF

3. A new clinical score for disease activity in Langerhans cell histiocytosis

Author

J.F. Emile, Mohamed-Aziz Barkaoui, Marie Ouache, T Généreau, Christophe Piguet, Jean Donadieu, H. Ibrahim, Frédéric Bernard, Yves Bertrand, Abdellatif Tazi, Caroline Thomas, and Olivier Hermine

Subjects
medicine.medical_specialty, Scoring system, Time Factors, Databases, Factual, Severity of Illness Index, Disease activity, Score distribution, Disease severity, Langerhans cell histiocytosis, Predictive Value of Tests, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, business.industry, Mortality rate, Hematology, Therapeutic evaluation, medicine.disease, Survival Analysis, Surgery, Histiocytosis, Langerhans-Cell, Oncology, Data Interpretation, Statistical, Pediatrics, Perinatology and Child Health, business, Statistical Distributions
Abstract

Objective To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). Method Scoring system was developed and applied to a database containing information on 612 patients. Results At diagnosis, the score distribution was highly asymmetrical: the score was between 0 and 2 in 74% of cases, 3-6 in 16%, 7-10 in 3%, and more than 10 in 6%. The 5-year mortality rates were 1, 4.4, and 43.4%, respectively, among patients with initial scores of 0-2, 3-6, and >6. Stability or an increase of the score at 6 weeks was highly predictive of death among patients with initial scores above 6, while score stability had no significant impact on vital outcome among patients with low or moderate scores at diagnosis. Conclusions This LCH disease activity score provides an objective tool for assessing disease severity, both at diagnosis and during follow-up and treatment.

Published
2004

4. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Juvenile Myelomonocytic Leukemia (JMML) in France: A Retrospective Study of Société Française De Greffe De Moelle Et De Thérapie Cellulaire

Author

Déborah Meyran, Marion Strullu, Karima Yakouben, Bénédicte Neven, Claire Galambrun, Raphaël Porcher, Marie Ouache, Patrick Lutz, and Nicole Raus

Subjects
Oncology, Transplantation, medicine.medical_specialty, Juvenile myelomonocytic leukemia, business.industry, medicine.medical_treatment, virus diseases, Retrospective cohort study, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Internal medicine, medicine, business
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results